Interferon-β-1a (Avonex) 30 mcg and 60 mcg are equally effective in patients with relapsing multiple sclerosis:: results from the Cyprus study site of the European IFNβ-1a Dose Comparison Study

被引：0
作者：
Kkolou, E [1 ]
Papacostas, S [1 ]
Kyriallis, K [1 ]
Toufexis, J [1 ]
Pantzaris, M [1 ]
机构：
[1] Cyprus Inst Neurol & Genet, Nicosia, Cyprus
来源：
MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [31] A randomized, controlled trial of interferon-β-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]
    Mark C Genovese
    Eliza F Chakravarty
    Eswar Krishnan
    Larry W Moreland
    [J]. Arthritis Res Ther, 6
  • [32] A randomized, controlled trial of interferon-β-1a (Avonex®) in patients with rheumatoid arthritis:: a pilot study [ISRCTN03626626]
    Genovese, MC
    Chakravarty, EF
    Krishnan, E
    Moreland, LW
    [J]. ARTHRITIS RESEARCH & THERAPY, 2004, 6 (01) : R73 - R77
  • [33] Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis:: A preliminary study
    Minagar, Alireza
    Adamashvili, Irena
    Kelley, Roger E.
    Gonzalez-Toledo, Eduardo
    McLarty, Jerry
    Smith, Stacy J.
    [J]. JOURNAL OF NEUROINFLAMMATION, 2007, 4 (1)
  • [34] Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study
    Alireza Minagar
    Irena Adamashvili
    Roger E Kelley
    Eduardo Gonzalez-Toledo
    Jerry McLarty
    Stacy J Smith
    [J]. Journal of Neuroinflammation, 4
  • [35] In vivo effect of interferon-β 1a on interleukin-12 and TGF-β1 cytokines in patients with relapsing-remitting multiple sclerosis
    Losy, J
    Michalowska-Wender, G
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (01): : 44 - 46
  • [36] A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
    Clanet, M
    Radue, EW
    Kappos, L
    Hartung, HP
    Hohlfeld, R
    Sandberg-Wollheim, M
    Kooijmans-Coutinho, M
    Tsao, EC
    Sandrock, AW
    [J]. NEUROLOGY, 2002, 59 (10) : 1507 - 1517
  • [37] Five years impact of subcutaneous interferon-β-1a on cognitive impairment in mildly disabled patients with relapsing-remitting multiple sclerosis: the COGIMUS study group
    Patti, F.
    Morra, V. Brescia
    Amato, M.
    Bastianello, S.
    Tola, M.
    Cottone, S.
    Lanzillo, R.
    Trojano, M.
    Centonze, D.
    Grimaldi, L. M. E.
    Gasperini, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 455 - 455
  • [38] Efficacy and safety of a new formulation of subcutaneous interferon β-1a in patients with relapsing-remitting multiple sclerosis: 40-week results from the IMPROVE study
    De Stefano, N.
    Curtin, F.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S231 - S231
  • [39] Phase IV Clinical Study to Evaluate the Efficacy and Safety of AVONEX® (Interferon-β-1a) in Japanese Subjects with Relapsing Form of Multiple Sclerosis (MS) and the Effect of Dose Titration on Severity and Incidence of Flu-like Symptoms (FLS)
    Saida, Takahiko
    Ueno, Yasuhiro
    Hirakata, Toshiyuki
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 925 - 925
  • [40] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
12345